Diabetes, use of metformin, and the risk of meningioma by Leitzmann, Michael F. et al.
RESEARCH ARTICLE
Diabetes, use of metformin, and the risk of
meningioma
Corinna Seliger1*, Christoph R. Meier2,3,4, Claudia Becker2, Susan S. Jick3,
Martin Proescholdt5, Ulrich Bogdahn1, Peter Hau1, Michael F. Leitzmann6
1 Department of Neurology and Wilhelm Sander-NeuroOncology Unit, Regensburg University Hospital,
Regensburg, Germany, 2 Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and
Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland, 3 Boston
Collaborative Drug Surveillance Program, Boston University School of Public Health, Boston University,
Boston, Massachusetts, United States of America, 4 Hospital Pharmacy, University Hospital Basel, Basel,
Switzerland, 5 Department of Neurosurgery, Regensburg University Hospital, Regensburg, Germany,
6 Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany
* corinna.seliger@klinik.uni-regensburg.de
Abstract
Background
Metformin is a commonly used oral antidiabetic agent that has been associated with
decreased cancer risk. However, data regarding the association between metformin use
and the risk of meningioma are unavailable.
Methods
We conducted a matched case-control analysis using data from the U.K.-based Clinical
Practice Research Datalink (CPRD) to analyse diabetes status, duration of diabetes, glyce-
mic control, and use of metformin, sulfonylureas, and insulin in relation to the risk of meningi-
oma. We conducted conditional logistic regression analyses to determine relative risks,
estimated as odds ratios (ORs) with 95% confidence intervals (CIs) and adjusted for body
mass index, smoking, history of arterial hypertension, myocardial infarction, and use of
estrogens (among women).
Results
We identified 2,027 meningioma cases and 20,269 controls. For diabetes there was the sug-
gestion of an inverse association with meningioma (OR = 0.89; 95%CI = 0.74–1.07), which
was driven by an inverse relation among women (OR = 0.78; 95%CI = 0.62–0.98), in whom
we also noted a suggestive inverse association with duration of diabetes (p-value for trend =
0.071). For metformin there was a suggestive positive relation, particularly after matching
on duration of diabetes and HbA1c level (OR = 1.64; 95%CI = 0.89–3.04). Sulfonylureas
showed no clear association (OR = 0.91; 95%CI = 0.46–1.80). For insulin there was the sug-
gestion of an inverse relation, in particular when comparing a high vs. low number of pre-
scriptions (OR = 0.58; 95%CI = 0.18–1.83).
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Conclusion
Further studies are needed to solidify a possible inverse association between diabetes and
meningioma risk and to clarify the role of antidiabetics in this context.
Introduction
Meningioma is a common meningeal intracranial or intraspinal tumor, affecting about 8
patients per 100.000 person-years [1]. The incidence of meningioma increases with age, affect-
ing men less often than women [1]. Established risk factors for meningioma are uncommon
and they include a history of ionizing radiation and rare genetic cancer syndromes [2].
Female sex hormones [3, 4], adiposity [5, 6], and arterial hypertension [6, 7] may be associ-
ated with increased risk of meningioma. However, there is conflicting evidence on whether
diabetes is positively related [8, 9], unrelated [10] or inversely [11, 12] related to the risk of
meningioma. Metformin is a frequently prescribed oral antidiabetic agent [13], which has
been associated with reduced cancer risk [14], but specific data regarding metformin use and
associated meningioma risk are unavailable. Metformin inhibits the mammalian target of
rapamycin (mTOR) [15]. Meningioma samples have been shown to express high levels of
mTORC1, indicating mTOR signalling as a relevant pathway in meningioma development
[16]. Further, inhibitors of mTORC1 reduce meningioma growth in mice [17]. However, the
only study investigating treatment of meningioma cells with metformin in vitro showed no
effects at clinically relevant doses [18].
The plausible underlying biological mechanisms and the sparse observational data regard-
ing diabetes and use of metformin in relation to the risk of meningioma prompted us to per-
form the current study.
Patients and methods
Data source
The Clinical Practice Research Datalink (CPRD) is a primary care database in the United
Kingdom (U.K.), which holds patient information on around 8.5% of the population of the U.
K. Patient data in the CPRD are representative of the U.K. general population with respect to
age, sex, and ethnicity. General practitioners record demographic data, physical findings,
symptoms, diagnoses, referrals, hospital admissions, drug prescriptions, and deaths in an
anonymous format using standard coding systems [19]. The CPRD has been extensively vali-
dated [20, 21] and found to be of high quality. The current study was reviewed and approved
by the Independent Scientific Advisory Committee of the CPRD (protocol-number 16–121)
and the protocol was made available to the journal reviewers.
Study population
The study population was comprised of all people in the CPRD during years 1995 to 2015 who
were age90 years.
Case definition. We defined cases as patients in the study population who had a first ever
Read code for meningioma during the indicated study time. See S1 Table for a list of Read
codes used to identify cases. The index date for each case was the date of diagnosis minus three
years. We did this to account for potential lag time between disease development and diagno-
sis, and to increase the likelihood of assessing exposure before meningioma onset to minimize
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bias due to early symptoms of undiagnosed meningioma, such as the earlier detection of pre-
existing concomitant diseases, or changes in drug adherence and usage patterns. We excluded
patients with less than three years of active history in the database before the index date, those
with a current or past history of other cancers except non-melanoma skin cancer and those
with recorded alcoholism or human immunodeficiency virus infection prior to the index date.
Control definition. We matched up to 10 controls for each case, randomly selected from
the study population, on sex, age (same year of birth ±2 years), calendar time (same index
date), general practice, and number of years of active history in the database prior to the index
date. We applied the same exclusion criteria to controls as to cases.
Exposures
We assessed use of metformin, sulfonylureas, and insulin before the index date for cases and
controls. We categorized exposure to antidiabetic drugs, based on the number of prescriptions
before the index date, into short-term use (1–9 prescriptions), medium-term use (10–29 pre-
scriptions), or long-term use ( 30 prescriptions). The number of prescriptions served as an
approximation of exposure duration, since an average prescription covers 45–90 days of treat-
ment, depending on the number of tablets (1 or 2) taken per day. Exposure was assessed sepa-
rately for each study drug. If more than one study drug was received, we mutually adjusted our
analyses for drug use, such that results relating use of a particular antidiabetic drug to risk of
meningioma were adjusted for combined or prior use of other antidiabetic drugs.
We assessed the presence of a diagnosis of diabetes mellitus, the duration of diabetes, and
the mean recorded glycosylated haemoglobin A1c (HbA1c) level from the computerized rec-
ords. Duration of diabetes was calculated by counting the days between the date of the first
documentation of a diabetes diagnosis and the respective index date. We classified duration of
diabetes into three categories (< 2 years, 2–5 years, > 5 years) for cases and controls, and
HbA1c levels into four categories (unknown, <6.5%, 6.5–7.9%, 8.0%). Our analysis was not
restricted to patients with type 2 diabetes. However, when we considered patients younger
than 30 years of age with insulin use as an estimation of patients with type 1 diabetes, only 2
patients in our dataset were deemed type 1 diabetics.
Statistical analysis
We conducted conditional logistic regression analysis using SAS statistical software version
9.4 (SAS Institute Inc, Cary, NC) to determine relative risks, estimated as odds ratios (ORs)
with 95% confidence intervals (CIs) of meningioma in relation to diabetes status, duration of
diabetes, level of glycemic control, and use of specific antidiabetic drugs. In univariate analy-
ses, we investigated the associations of meningioma to various potential confounding vari-
ables, including presence versus absence (reference) of specific medical conditions, diseases or
medications, such as dyslipidemia, stroke, transient ischemic attack (TIA), ischemic heart dis-
ease (IHD), myocardial infarction (MI), congestive heart failure (CHF), and renal failure; and
use of statins, non-steroidal anti-inflammatory drugs, and aspirin. We included variables that
were significantly associated with risk of meningioma in univariate analyses in the final multi-
variate analysis in addition to BMI, smoking status, and arterial hypertension. Analyses were
also performed without adjustment for BMI to prevent statistical over control.
We conducted tests of linear trend by modeling the median value of duration of diabetes,
HbA1 level, or drug prescription category as a continuous variable in the multivariate model,
the coefficient for which was evaluated using a Wald test. We considered a two-sided p-value
of<0.05 statistically significant.
Metformin and meningioma
PLOS ONE | https://doi.org/10.1371/journal.pone.0181089 July 14, 2017 3 / 11
We stratified our results by age and sex and reported the relevant differences in the text.
We also performed subanalyses restricted to diabetic patients and we additionally matched on
diabetes, duration of diabetes, and both duration of diabetes and HbA1c level.
Results
We ascertained 2,027 cases and 20,269 controls in the CPRD database. Cases and matched
controls had a mean age ± standard deviation (SD) of 61.6 ± 15.2 years at the index date, and
most cases were women (75.7%). The mean number of years of active history in the database
was 11.2 ± 5.0 years before the index date. As compared to normal weight (BMI 18.5–24.9 kg/
m2), overweight (BMI 25–30 kg/m2) was suggestively related to increased risk of meningioma
(OR = 1.13; 95%CI = 1.00–1.27) and obesity (BMI30 kg/m2) was statistically significantly
associated with increased risk of meningioma (OR for obesity = 1.31; 95%CI = 1.15–1.50).
Table 1 displays general characteristics of meningioma cases and controls. Cases and con-
trols were similar with respect to most covariates. Use of 1–8 prescriptions of estrogens in
women (OR = 1.39; 95%CI = 1.18–1.63) was associated with a small increased risk of meningi-
oma, whereas the opposite was true for history of myocardial infarction (OR = 0.67; 95%
CI = 0.49–0.91). No associations with meningioma were found for dyslipidemia, stroke, CHF,
renal failure, and use of statins, non-steroidal-anti-inflammatory drugs, and aspirin.
Diabetes mellitus was associated with a statistically non-significant decreased risk of menin-
gioma (OR = 0.89, 95%CI = 0.74–1.07) (Table 2). Stratification by sex revealed an inverse rela-
tion of diabetes and risk of meningioma in women (OR = 0.78; 95%CI = 0.62–0.98) but not
men (OR = 1.17; 95%CI = 0.85–1.61), whereas the relation did not vary according to age.
Among the 90 diabetic women, 32 (35.6%) were using exogenous estrogens.
When we restricted the analysis to those women, the inverse association between diabetes
and risk of meningioma was lost (OR = 1.09; 95%CI = 0.69–1.75). In the overall study popula-
tion, there was no clear trend regarding increasing duration of diabetes (p-value for trend for
increasing duration of diabetes = 0.423) or level of glycemic control (p-value for trend for
increasing HbA1c = 0.977) and the risk of meningioma. In women however, there was a bor-
derline significant inverse association between increasing duration of diabetes and meningi-
oma risk (p-value for trend = 0.071). Results were similar when we removed BMI from the
analysis, though the previously observed inverse association between diabetes and meningi-
oma in women was no longer statistically significant (OR = 0.83; 95%CI = 0.66–1.05), nor was
the previously observed borderline significant trend of increasing duration of diabetes and risk
of meningioma in women (p-value for trend = 0.188).
Use of 10 metformin prescriptions or more was associated with a statistically non-signifi-
cant increased risk of meningioma (OR for30 prescriptions = 1.16; 95%CI = 0.76–1.77,
Table 3). When we restricted the analysis to diabetic patients, 90 diabetic cases (62.1% of dia-
betic cases) and 857 diabetic controls (58.5% of diabetic controls) were taking metformin.
When analysing a newly matched dataset containing diabetic patients only, use of metformin
was associated with a non-significantly increased risk of meningioma (OR for use versus non-
use of metformin = 1.16; 95%CI = 0.77–1.76; OR for30 prescriptions = 1.27; 95%CI = 0.79–
2.04). The relation strengthened after matching on duration of diabetes and HbA1c level (OR
for30 prescriptions = 1.64; 95%CI = 0.89–3.04, p-value for trend = 0.059). When we strati-
fied by sex, the positive test for trend regarding the association between metformin use and
risk of meningioma in analyses matched by duration of diabetes and HbA1c level was statisti-
cally significant in women (p-value for trend = 0.033).
We found no clear association between sulfonylureas and meningioma, even when we
restricted the analysis to patients with diabetes and matched them on duration of diabetes and
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HbA1c level (p-value for trend = 0.664). By comparison, the number of insulin prescriptions
showed a statistically non-significant inverse relation to meningioma (p-value for trend =
0.147). When we matched on duration of diabetes and HbA1c level, the trend was attenuated
(p-value for trend = 0.391). This held true for both men (p-value for trend = 0.759) and
women (p-value for trend = 0.359). Results did not change materially when BMI was not
adjusted for, although 52.2% of long-term users of metformin had a BMI30 kg/m2.
Table 1. Characteristics of meningioma cases and controls.
Variable Number of cases (%) (n = 2,027) Number of controls (%) (n = 20,269) Crude OR (95%CI) p-value
Age (years)a
0–9 1 (0.1) 10 (0.1) - -
10–19 17 (0.8) 173 (0.9) - -
20–29 24 (1.2) 261 (1.3) - -
30–39 117 (5.8) 1,161 (5.7) - -
40–49 301 (14.9) 3,018 (14.9) - -
50–59 396 (19.5) 3,963 (19.6) - -
60–69 455 (22.5) 4,526 (22.3) - -
70–79 461 (22.7) 4,638 (22.9) - -
80–90 255 (12.6) 2,519 (12.4)
Sex a
Women 1,534 (75.7) 15,340 (75.7) - -
Men 493 (24.3) 4,929 (24.3) - -
Comorbidities
Dyslipidemia 228 (11.3) 2,110 (10.4) 1.11 (0.95–1.29) 0.207
Stroke/TIA 89 (4.4) 958 (4.7) 0.92 (0.73–1.16) 0.481
CHF 43 (2.12) 449 (2.5) 0.85 (0.61–1.18) 0.326
MI 45 (2.2) 656 (3.2) 0.67 (0.49–0.91) 0.011
Renal Failure 53 (2.6) 514 (2.5) 1.03 (0.77–1.38) 0.828
Statins
No prior use 1,669 (82.3) 16,753 (82.7) 1.00 (referent) -
1–9 Rx 99 (4.9) 842 (4.2) 1.18 (0.95–1.48) 0.135
10 Rx 259 (12.8) 2,674 (13.2) 0.98 (0.83–1.14) 0.747
NSAIDs
No prior use 528 (26.1) 5,583 (27.5) 1.00 (referent) -
1–9 Rx 1,364 (67.3) 13,456 (66.4) 1.09 (0.97–1.22) 0.153
10 Rx 135 (6.7) 1,230 (6.1) 1.19 (0.96–1.46) 0.112
Aspirin
No prior use 1,953 (96.4) 19,523 (96.3) 1.00 (referent) -
1–14 Rx 57 (2.8) 533 (2.6) 1.07 (0.81–1.42) 0.647
15 Rx 17 (0.8) 213 (1.05) 0.79 (0.48–1.31) 0.367
Estrogensb
No prior use 1,113 (72.6) 11,685 (76.2) 1.00 (referent) -
1–8 Rx 241 (15.7) 1,922 (12.5) 1.39 (1.18–1.63) <0.0001
9 Rx 180 (11.7) 1,733 (11.3) 1.16 (0.97–1.40) 0.105
aMatching variables: age, sex, general practice, and number of years of active history in the database.
bWomen only.
BMI: Body Mass Index; TIA: transient ischemic attack; CHF: congestive heart failure; MI: myocardial infarction; NSAIDs: non-steroidal anti-inflammatory
drugs; OR: odds ratio; Rx: total number of prescriptions prior to index date.
https://doi.org/10.1371/journal.pone.0181089.t001
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Discussion
Our matched case-control analysis revealed a suggestive inverse association of diabetes with
meningioma, which was driven by an inverse relation among women, in whom we also noted
a suggestive inverse association with duration of diabetes.
In prior investigations, positive [8, 9], null [10], and statistically non-significant [12] or sig-
nificant inverse associations [11] were observed between diabetes and the risk of meningioma.
A German case-control study based on 306 meningioma patients found a positive association
with diabetes that was restricted to certain age- and gender groups (50–69 years for men, 40–
49 years and 60–69 years for women) (ORs ranging from 4.30 to 13.94 with p-values ranging
from 0.001 to 0.05), but that study did not adjust for possible confounding factors such as BMI
or arterial hypertension [8]. A Swedish study [9] including 4,193 meningioma patients differed
from our study in that the diagnosis of diabetes was based on hospital discharge letters, which
results in the detection of more severe and long-lasting cases of diabetes. In that study, the OR
for meningioma in diabetic men increased beginning 6 to 7 years before brain tumor diagno-
sis, but in diabetic women, as in our study, the ORs for meningioma initially declined (p-value
for trend = 0.02) until 1 to 2 years before meningioma diagnosis. A recent cohort study based
Table 2. Risk of meningioma in relation to diabetes status, duration of diabetes, and HbA1c level, overall and stratified by sex and age.
Variable Number of cases (%) n = 2,027 Number of controls (%) n = 20,269 Adjusted ORa (95%CI)
Total meningioma
Diabetes 145 (7.2) 1,465 (7.2) 0.89 (0.74–1.07)
Women
Diabetes 90 (5.9) 1,001 (6.5) 0.78 (0.62–0.98)
Men
Diabetes 55 (11.2) 464 (9.4) 1.17 (0.85–1.61)
<40 years
Diabetes 0 (0.0) 18 (1.1) n.e.
40–69 years
Diabetes 64 (5.6) 592 (5.1) 0.93 (0.70–1.23)
>69 years
Diabetes 81 (11.3) 855 (12.0) 0.88 (0.68–1.29)
Total glioma
Duration of Diabetes
Non-diabetic 1,882 (92.9) 18,804 (92.8) 1.00 (referent)
< 2 years 24 (1.2) 229 (1.1) 0.93 (0.61–1.42)
2–5 years 32 (1.6) 375 (1.9) 0.75 (0.52–1.08)
> 5 years 89 (4.4) 861 (4.3) 0.94 (0.74–1.18)
p-value for trend 0.423
HbA1c level
Unknown 1,858 (91.7) 18,700 (92.3) 1.05 (0.83–1.31)
< 6.5% 96 (4.7) 927 (4.6) 1.00 (referent)
6.5–7.9% 40 (2.0) 314 (1.6) 1.19 (0.81–1.77)
 8.0% 33 (1.6) 328 (1.6) 0.97 (0.64–1.47)
p-value for trend 0.977
aMatched on age, sex, general practice, and number of years of active history in the database, and adjusted for BMI, smoking, arterial hypertension, MI, and
use of estrogens.
The p-value for trend did not include subjects with unknown HbA1c level.
https://doi.org/10.1371/journal.pone.0181089.t002
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on 296 meningioma patients derived from the Apolipoprotein MOrtality RISk (AMORIS)
cohort found that diabetes was inversely related to meningioma for both sexes combined
(HR = 0.45; 95%CI = 0.29–0.71) and the authors specifically discussed the possibility that the
decreased risk of meningioma in diabetic patients may be attributed to metformin use, which
they did not evaluate in their study, and they were also not able to stratify by sex due to small
numbers [11]. A large hospital-based case-control study also found an inverse association
between diabetes and risk of meningioma, but results did not reach statistical significance
(OR = 0.67; 95%CI = 0.37–1.20), whereas an international population-based case-control
study showed no clear relation of diabetes to meningioma [10].
One prior study investigating risk of meningioma in relation to fasting serum glucose levels
found no association between the two [7], whereas another study found an inverse relation of
Table 3. Risk of meningioma in relation to number of prescriptions for anti-diabetic drugs.
Antidiabetic drug
and no. of
prescriptions
Meningioma cases and controls Diabetic meningioma cases and
controls, matched on duration of
diabetes
Diabetic meningioma cases and
controls, matched on duration of
diabetes and HbA1c level
Cases (%)
(n = 2,027)
Controls (%)
(n = 20,269)
Adjusted
ORa (95%CI)
Cases (%)
(n = 142)
Controls (%)
(n = 1,328)
Adjusted
ORa (95%CI)
Cases (%)
(n = 125)
Controls
(%)
(n = 837)
Adjusted
ORa (95%CI)
Metformin
0 1,932 (95.3) 19,395 (95.7) 1.00
(referent)
53 (37.3) 514 (38.7) 1.00
(referent)
47 (37.6) 401 (47.9) 1.00
(referent)
1–9 18 (0.9) 209 (1.0) 0.88 (0.52–
1.47)
17 (12.0) 196 (14.8) 0.99 (0.54–
1.80)
17 (13.6) 133 (15.9) 0.84 (0.43–
1.64)
10–29 34 (1.7) 275 (1.4) 1.25 (0.83–
1.89)
30 (21.1) 244 (18.4) 1.40 (0.83–
2.37)
28 (22.4) 150 (17.9) 1.42 (0.78–
2.58)
30 43 (2.1) 390 (1.9) 1.16 (0.76–
1.77)
42 (29.6) 374 (28.2) 1.20 (0.69–
2.08)
33 (26.4) 153 (18.3) 1.64 (0.89–
3.04)
p-value for trend 0.403 0.498 0.059
Sulfonylureas
0 1,962 (96.8) 19,572 (96.6) 1.00
(referent)
79 (55.6) 670 (50.5) 1.00
(referent)
73 (58.4) 534 (63.8) 1.00
(referent)
1–9 15 (0.7) 134 (0.7) 0.94 (0.53–
1.69)
15 (10.6) 139 (10.5) 0.81 (0.43–
1.52)
15 (12.0) 76 (9.1) 1.27 (0.65–
2.45)
10–29 12 (0.6) 208 (1.03) 0.50 (0.26–
0.93)
12 (8.5) 189 (14.2) 0.49 (0.25–
0.96)
10 (8.0) 115 (13.7) 0.45 (0.21–
0.98)
30 38 (1.9) 355 (1.8) 0.91 (0.58–
1.42)
36 (25.4) 330 (24.9) 0.68 (0.39–
1.17)
27 (21.6) 112 (13.4) 0.91 (0.46–
1.80)
p-value for trend 0.673 0.212 0.664
Insulin
0 2,006 (99.0) 19,964 (98.5) 1.00
(referent)
122 (85.9) 1,114 (83.9) 1.00
(referent)
112 (89.6) 763 (91.2) 1.00
(referent)
1–9 3 (0.2) 62 (0.3) 0.41 (0.13–
1.36)
3 (2.1) 44 (3.3) 0.66 (0.20–
2.24)
3 (2.4) 20 (2.4) 1.11 (0.30–
4.19)
10–29 7 (0.4) 76 (0.4) 0.84 (0.38–
1.89)
7 (4.9) 50 (3.8) 1.00 (0.41–
2.50)
4 (3.2) 17 (2.0) 1.39 (0.35–
5.48)
30 11 (0.5) 167 (0.8) 0.62 (0.33–
1.17)
10 (7.0) 120 (9.0) 0.56 (0.25–
1.26)
6 (4.8) 37 (4.4) 0.58 (0.18–
1.83)
p-value for trend 0.147 0.171 0.391
aMatched on age, sex, general practice, and number of years of active history in the database, and adjusted for BMI, smoking, MI, arterial hypertension,
estrogen use, and all antidiabetics used by the study population.
https://doi.org/10.1371/journal.pone.0181089.t003
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fasting serum glucose to meningioma risk in women [11], but both those investigations dif-
fered from our study since we investigated HbA1c and not fasting serum glucose levels.
One possible explanation for the inverse association between diabetes and meningioma in
women observed in our study is that diabetic women partly suffer from a reduced ability to
convert androgens to estrogens in the ovaries [22], and female sex hormones are proposed to
increase the risk of meningioma [3, 4]. This hypothesis is supported by the fact that the inverse
association between diabetes and risk of meningioma was lost in women taking exogenous
estrogens. Because diabetes and antidiabetic treatment are closely interrelated, it is challenging
to examine the risk of meningioma in relation to diabetes per se, without considering the use
of antidiabetic drugs. Therefore, in our main analyses we focused on antidiabetic medications
but we conducted important additional analyses that accounted for duration of diabetes and
HbA1c level.
Use of sulfonylureas showed no clear association with meningioma, whereas for insulin
there was the suggestion of an inverse relation, in particular, when comparing a high vs. low
number of prescriptions. For metformin, there was an unexpected borderline statistically sig-
nificant positive association with meningioma risk in analyses matched on duration of diabetes
and level of glycemic control, which was rendered statistically significant in the test for trend
restricted to women. Possibly, metformin use leads to hormonal changes in women, such as
reduction of luteinizing or follicle stimulation hormone as observed in polycystic ovary syn-
drome [23], which may influence free estradiol levels and thereby risk of meningioma. In addi-
tion, although we adjusted our analyses for BMI, we cannot fully exclude residual confounding
by adiposity. Metformin is the first-line treatment for obese type-II diabetic patients, which
may lead to a higher proportion of obese patients taking metformin [24].
The fact that metformin inhibits mTOR in experimental models [15] but shows no inhibi-
tory effects on meningioma development, where mTOR signalling plays an important role [16,
17], may be explained by several factors. Antidiabetic doses of metformin may not be sufficient
to inhibit mTOR in meningioma development, though metformin passes the blood-brain bar-
rier [25]. Consistent with this hypothesis, meningioma cells treated with clinically relevant doses
of metformin were not significantly inhibited in vitro [18]. Also, even though mTOR signalling
is an important pathogenic factor for established meningiomas, its blockage might not inhibit
initial meningioma development. Additionally, the sample size of diabetic meningioma patients
taking metformin in our study may not have been sufficient to detect significant results.
Certain potential shortcomings of our study need to be discussed. Data on ionizing radia-
tion, the only known modifiable risk factor for meningioma [26], were not available in the
CPRD. However, the proportion of meningioma cases due to radiation is small, and patients
with cancers other than non-melanoma skin cancer were excluded from the study population.
Another limitation is missing information on molecular subtype or degree of malignancy of
the investigated meningiomas. Socioeconomic status, education level, and lifestyle factors [5,
27] were not taken into account in our analyses due to limited information on these variables,
but may influence meningioma risk. Also, we may have under-ascertained patients with
meningioma diagnosis due to subclinical meningiomas [28], but the number of undiagnosed
meningioma patients should not differ substantially between cases and controls, especially
after shifting the index date back in time by three years. Additionally, although shifting the
index date backwards in time by three years, we may have failed to encompass the true latency
period of meningiomas due to their slow growing behaviour. Finally, we cannot fully rule out
confounding by indication. For example, metformin may have been used in less severe cases of
diabetes compared to insulin [29]. Hence, our analyses of antidiabetic drugs in relation to risk
of meningioma were adjusted for duration of diabetes and HbA1c level to account for differ-
ences in diabetes severity.
Metformin and meningioma
PLOS ONE | https://doi.org/10.1371/journal.pone.0181089 July 14, 2017 8 / 11
Our study has a number of notable strengths. To the best of our knowledge, the current
study is the first to comprehensively evaluate the relations of diabetes, duration of diabetes,
level of glycemic control, and antidiabetic drug use to risk of meningioma. Additionally, we
performed a number of sensitivity analyses, such as matching on duration of diabetes and level
of glycemic control. The CPRD is a well-validated and large database [20]. Cases and controls
were generated from a pre-existing database, which minimized selection bias. Further, there
was no recall bias because the data on medications and concomitant diseases were collected
prospectively and without a pre-specified study hypothesis. We shifted the index date back in
time by three years to account for various potential biases. Finally, we excluded patients with
less than three years of active history in the CPRD before the index date in order to increase
the chance of including incident meningioma cases.
In summary, diabetes was inversely related to risk of meningioma among women, whereas
increasing use of metformin was associated with increased risk of meningioma among
women. Our study does not provide evidence for a protective association of metformin use to
meningioma risk. Further research is however needed to evaluate whether metformin use is
potentially associated with improved survival of meningioma patients.
Supporting information
S1 Table. READ codes for meningioma used in this study and corresponding descriptions.
(DOCX)
Acknowledgments
We thank Pascal Egger for technical support and programming and all members of the KFO
262 for critical discussions regarding our manuscript.
Author Contributions
Conceptualization: Corinna Seliger, Christoph R. Meier, Claudia Becker, Susan S. Jick, Peter
Hau, Michael F. Leitzmann.
Data curation: Corinna Seliger, Christoph R. Meier, Claudia Becker, Susan S. Jick.
Formal analysis: Corinna Seliger, Claudia Becker, Michael F. Leitzmann.
Funding acquisition: Corinna Seliger, Michael F. Leitzmann.
Investigation: Corinna Seliger, Claudia Becker.
Methodology: Corinna Seliger, Christoph R. Meier, Claudia Becker, Susan S. Jick, Michael F.
Leitzmann.
Project administration: Corinna Seliger, Christoph R. Meier, Claudia Becker, Michael F.
Leitzmann.
Resources: Christoph R. Meier, Michael F. Leitzmann.
Software: Corinna Seliger, Michael F. Leitzmann.
Supervision: Christoph R. Meier, Susan S. Jick, Martin Proescholdt, Peter Hau, Michael F.
Leitzmann.
Validation: Corinna Seliger, Claudia Becker, Michael F. Leitzmann.
Visualization: Corinna Seliger.
Writing – original draft: Corinna Seliger, Michael F. Leitzmann.
Metformin and meningioma
PLOS ONE | https://doi.org/10.1371/journal.pone.0181089 July 14, 2017 9 / 11
Writing – review & editing: Christoph R. Meier, Claudia Becker, Susan S. Jick, Martin
Proescholdt, Ulrich Bogdahn, Peter Hau, Michael F. Leitzmann.
References
1. Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C et al. CBTRUS Statistical Report: Primary
Brain and Central Nervous System Tumors Diagnosed in the United States in 2008–2012. Neuro-oncol-
ogy. 2015; 17 Suppl 4: iv1–iv62.
2. Saraf S, McCarthy BJ, Villano JL. Update on meningiomas. The oncologist. 2011; 16: 1604–13. https://
doi.org/10.1634/theoncologist.2011-0193 PMID: 22028341
3. Benson VS, Kirichek O, Beral V, Green J. Menopausal hormone therapy and central nervous system
tumor risk: large UK prospective study and meta-analysis. International journal of cancer. 2015; 136:
2369–77. https://doi.org/10.1002/ijc.29274 PMID: 25335165
4. Claus EB, Calvocoressi L, Bondy ML, Wrensch M, Wiemels JL, Schildkraut JM. Exogenous hormone
use, reproductive factors, and risk of intracranial meningioma in females. Journal of neurosurgery.
2013; 118: 649–56. https://doi.org/10.3171/2012.9.JNS12811 PMID: 23101448
5. Niedermaier T, Behrens G, Schmid D, Schlecht I, Fischer B, Leitzmann MF. Body mass index, physical
activity, and risk of adult meningioma and glioma: A meta-analysis. Neurology. 2015; 85: 1342–50.
https://doi.org/10.1212/WNL.0000000000002020 PMID: 26377253
6. Seliger C, Meier CR, Becker C, Jick SS, Proescholdt M, Bogdahn U et al. Metabolic syndrome in rela-
tion to risk of meningioma. Oncotarget. 2016.
7. Edlinger M, Strohmaier S, Jonsson H, Bjorge T, Manjer J, Borena WT et al. Blood pressure and other
metabolic syndrome factors and risk of brain tumour in the large population-based Me-Can cohort
study. Journal of hypertension. 2012; 30: 290–6. https://doi.org/10.1097/HJH.0b013e32834e9176
PMID: 22179083
8. Schneider B, Pulhorn H, Rohrig B, Rainov NG. Predisposing conditions and risk factors for development
of symptomatic meningioma in adults. Cancer detection and prevention. 2005; 29: 440–7. https://doi.
org/10.1016/j.cdp.2005.07.002 PMID: 16188400
9. Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Malmer B, Lonn S et al. Prior hospitalization
for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk. Cancer Epidemiol Bio-
markers Prev. 2005; 14: 643–50. https://doi.org/10.1158/1055-9965.EPI-04-0119 PMID: 15767344
10. Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A et al. Role of medical his-
tory in brain tumour development. Results from the international adult brain tumour study. International
journal of cancer. 1999; 82: 155–60. PMID: 10389745
11. Bernardo BM, Orellana RC, Weisband YL, Hammar N, Walldius G, Malmstrom H et al. Association
between prediagnostic glucose, triglycerides, cholesterol and meningioma, and reverse causality. Brit-
ish journal of cancer. 2016; 115: 108–14. https://doi.org/10.1038/bjc.2016.157 PMID: 27253176
12. Brenner AV, Linet MS, Fine HA, Shapiro WR, Selker RG et al. History of allergies and autoimmune dis-
eases and risk of brain tumors in adults. International journal of cancer. 2002; 99: 252–9. https://doi.
org/10.1002/ijc.10320 PMID: 11979441
13. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Medical oncology
(Northwood, London, England). 2012; 29: 1314–27.
14. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer
in diabetic patients. BMJ (Clinical research ed. 2005; 330: 1304–5. https://doi.org/10.1136/bmj.38415.
708634.F7 PMID: 15849206
15. Birsoy K, Sabatini DM, Possemato R. Untuning the tumor metabolic machine: Targeting cancer metab-
olism: a bedside lesson. Nature medicine. 2012; 18: 1022–3. https://doi.org/10.1038/nm.2870 PMID:
22772555
16. Surace EI, Lusis E, Haipek CA, Gutmann DH. Functional significance of S6K overexpression in menin-
gioma progression. Annals of neurology. 2004; 56: 295–8. https://doi.org/10.1002/ana.20201 PMID:
15293284
17. Pachow D, Andrae N, Kliese N, Angenstein F, Stork O, Wilisch-Neumann A et al. mTORC1 inhibitors
suppress meningioma growth in mouse models. Clin Cancer Res. 2013; 19: 1180–9. https://doi.org/10.
1158/1078-0432.CCR-12-1904 PMID: 23406776
18. Wilisch-Neumann A, Pachow D, Wallesch M, Petermann A, Bohmer FD, Kirches E et al. Re-evaluation
of cytostatic therapies for meningiomas in vitro. Journal of cancer research and clinical oncology. 2014;
140: 1343–52. https://doi.org/10.1007/s00432-014-1683-6 PMID: 24816784
Metformin and meningioma
PLOS ONE | https://doi.org/10.1371/journal.pone.0181089 July 14, 2017 10 / 11
19. Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997; 350: 1097–9.
https://doi.org/10.1016/S0140-6736(97)04248-7 PMID: 10213569
20. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR et al. Validity
of the general practice research database. Pharmacotherapy. 2003; 23: 686–9. PMID: 12741446
21. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research
Database: a systematic review. Br J Gen Pract. 2010; 60: e128–36. https://doi.org/10.3399/
bjgp10X483562 PMID: 20202356
22. Stamataki KE, Spina J, Rangou DB, Chlouverakis CS, Piaditis GP. Ovarian function in women with
non-insulin dependent diabetes mellitus. Clinical endocrinology. 1996; 45: 615–21. PMID: 8977760
23. Zahra M, Shah M, Ali A, Rahim R. Effects of Metformin on Endocrine and Metabolic Parameters in
Patients with Polycystic Ovary Syndrome. Hormone and metabolic research = Hormon- und Stoffwech-
selforschung = Hormones et metabolisme. 2016.
24. Scheen AJ, Lefebvre PJ. Pharmacological treatment of the obese diabetic patient. Diabete & metabo-
lisme. 1993; 19: 547–59.
25. Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B. Quantification of metformin by the
HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide.
Pharmacol Rep. 2010; 62: 956–65. PMID: 21098880
26. Inskip PD, Linet MS, Heineman EF. Etiology of brain tumors in adults. Epidemiologic reviews. 1995;
17: 382–414. PMID: 8654518
27. Benson VS, Pirie K, Green J, Casabonne D, Beral V. Lifestyle factors and primary glioma and meningi-
oma tumours in the Million Women Study cohort. British journal of cancer. 2008; 99: 185–90. https://
doi.org/10.1038/sj.bjc.6604445 PMID: 18560401
28. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP et al. Incidental findings on
brain MRI in the general population. The New England journal of medicine. 2007; 357: 1821–8. https://
doi.org/10.1056/NEJMoa070972 PMID: 17978290
29. Nathan DM, Davidson MB, Ferrannini E, Holman R, Sherwin R., Zinman B. Medical Management of
Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
A consensus statement of the American Diabetes Association and the European Association for the
Study of Diabetes. Diabetes Care. 2009; 193–203. https://doi.org/10.2337/dc08-9025 PMID: 18945920
Metformin and meningioma
PLOS ONE | https://doi.org/10.1371/journal.pone.0181089 July 14, 2017 11 / 11
